GO
Loading...

Bristol-Myers Squibb Co

More

  • Midday Glance: Pharmaceuticals companies Monday, 20 Apr 2015 | 1:17 PM ET

    Baxter International Inc. rose$. 56 or. 8 percent, to $70.47. Bristol-Myers Squibb Co. rose$. 56 or. 9 percent, to $65.91. Eli Lilly& Co. fell$. 10 or. 1 percent, to $72.38.

  • Early Glance: Pharmaceuticals companies Monday, 20 Apr 2015 | 10:38 AM ET

    Baxter International Inc. rose$. 34 or. 5 percent, to $70.25. Bristol-Myers Squibb Co. rose$. 28 or. 4 percent, to $65.63. Eli Lilly& Co. rose$. 38 or. 5 percent, to $72.85.

  • PHILADELPHIA— Giving patients with advanced melanoma two Bristol-Myers drugs that work differently held the deadly skin cancer at bay far longer than just one, though the combination's considerable increase in serious side effects raises concerns about how much patients can endure. In the midstage study, presented Monday at the American Association for...

  • TRENTON, N.J.— One of the hot new cancer immunotherapy drugs, Merck& Co.' s Keytruda, strongly benefited patients with melanoma, lung cancer and mesothelioma, according to three studies presented Sunday at the American Association for Cancer Research conference in Philadelphia. One study, comparing Keytruda to Bristol-Myers Squibb Co.' s Yervoy, could give Merck...

  • Final Glance: Pharmaceuticals companies Friday, 17 Apr 2015 | 6:03 PM ET

    Baxter International Inc. fell$. 24 or. 3 percent, to $69.91. Hospira fell$. 21 or. 2 percent, to $87.46. Johnson& Johnson fell$. 21 or. 2 percent, to $99.58.

  • April 17- A large study of Bristol-Myers Squibb Co's Opdivo treatment has been halted after proving the drug is effective against the most common form of lung cancer, the company said, positioning the medicine for far wider use than its already approved lung cancer and melanoma indications. AstraZeneca Plc, Pfizer Inc and other drugmakers are developing their...

  • Midday Glance: Pharmaceuticals companies Friday, 17 Apr 2015 | 1:17 PM ET

    Baxter International Inc. fell$. 23 or. 3 percent, to $69.92. Bristol-Myers Squibb Co. rose $1.84 or 2.9 percent, to $65.52. Eli Lilly& Co. fell$. 97 or 1.3 percent, to $72.52.

  • NYSE stocks posting largest percentage increases Friday, 17 Apr 2015 | 1:17 PM ET

    NEW YORK— A look at the 10 biggest percentage gainers on New York Stock Exchange at the close of trading:. Celanese Corp. rose 15.5 percent to $67.18. Summit Materials rose 6.8 percent to $23.59.

  • A promising treatment from Bristol-Myers Squibb may be fast-tracking toward another approved use after researchers stopped a study early because the drug did better than an older treatment in patients with an advanced form of lung cancer. Shares of the New York drugmaker jumped Friday morning after it said Opdivo fared better than the chemotherapy drug...

  • Early Glance: Pharmaceuticals companies Friday, 17 Apr 2015 | 10:57 AM ET

    Baxter International Inc. fell$. 23 or. 3 percent, to $69.92. Bristol-Myers Squibb Co. rose $1.68 or 2.6 percent, to $65.36. Johnson& Johnson fell$. 23 or. 2 percent, to $99.56.

  • Final Glance: Pharmaceuticals companies Thursday, 16 Apr 2015 | 6:03 PM ET

    Baxter International Inc. fell$. 05 or. 1 percent, to $70.15. Bristol-Myers Squibb Co. rose$. 25 or. 4 percent, to $63.68. Hospira fell$. 02 or percent, to $87.67.

  • Midday Glance: Pharmaceuticals companies Thursday, 16 Apr 2015 | 1:29 PM ET

    Baxter International Inc. fell$. 12 or. 2 percent, to $70.08. Bristol-Myers Squibb Co. rose$. 19 or. 3 percent, to $63.62. Eli Lilly& Co. fell$. 10 or. 1 percent, to $73.61.

  • Former Teva CEO's new gig at Ovid Therapeutics Thursday, 16 Apr 2015 | 6:10 AM ET

    After an abrupt departure, Former Teva CEO Jeremy Levin is now leading a start-up focused on rare neurological disorders.

  • Final Glance: Pharmaceuticals companies Wednesday, 15 Apr 2015 | 5:57 PM ET

    Baxter International Inc. rose$. 22 or. 3 percent, to $70.20. Bristol-Myers Squibb Co. fell$. 60 or. 9 percent, to $63.43. Eli Lilly& Co. rose$. 25 or. 3 percent, to $73.71.

  • April 15- The Medicines Co's intravenous blood clot preventer can be used in angioplasty procedures, an independent advisory panel to the U.S. Food and Drug Administration said on Wednesday. The recommendation follows a review published by FDA staff on Monday, which supported the approval of the drug. Cangrelor, which won European approval in March, was...

  • Midday Glance: Pharmaceuticals companies Wednesday, 15 Apr 2015 | 2:34 PM ET

    Baxter International Inc. rose$. 48 or. 7 percent, to $70.46. Bristol-Myers Squibb Co. fell$. 27 or. 4 percent, to $63.76. Eli Lilly& Co. rose$. 19 or. 3 percent, to $73.65.

  • LONDON, April 15- Having seen off a hostile $118 billion bid launched a year ago by U.S. rival Pfizer, Anglo-Swedish company AstraZeneca is on the move-- quite literally. Chief Executive Pascal Soriot is making AstraZeneca more nimble as hopes build for its cancer pipeline, but he still has his work cut out to keep 2015 earnings above the floor needed to protect his...

  • Final Glance: Pharmaceuticals companies Tuesday, 14 Apr 2015 | 5:58 PM ET

    Baxter International Inc. rose$. 11 or. 2 percent, to $69.98. Bristol-Myers Squibb Co. rose$. 08 or. 1 percent, to $64.03. Eli Lilly& Co. fell$. 06 or. 1 percent, to $73.46.

  • Midday Glance: Pharmaceuticals companies Tuesday, 14 Apr 2015 | 1:34 PM ET

    Baxter International Inc. rose$. 02 or percent, to $69.89. Bristol-Myers Squibb Co. rose$. 28 or. 4 percent, to $64.23. Hospira rose$. 04 or percent, to $87.68.

  • Early Glance: Pharmaceuticals companies Tuesday, 14 Apr 2015 | 10:42 AM ET

    Baxter International Inc. fell$. 13 or. 2 percent, to $69.74. Bristol-Myers Squibb Co. fell$. 24 or. 4 percent, to $63.71. Eli Lilly& Co. fell$. 27 or. 4 percent, to $73.25.